**Question:** All are true about statin therapy in a case of CHF except a'.

A. Statins lower cholesterol levels and reduce the risk of cardiovascular events.
B. Statins improve cardiac contractility and reduce heart failure symptoms.
C. Statins increase the risk of myopathy and rhabdomyolysis in heart failure patients.
D. Statins have no effect on inflammatory markers in heart failure.

**Correct Answer:** B. Statins improve cardiac contractility and reduce heart failure symptoms.

**Core Concept:** Statins are a class of medications primarily used for lowering cholesterol levels and reducing the risk of cardiovascular events. They predominantly act on HMG-CoA reductase enzyme, which is crucial for cholesterol synthesis in the liver. In cases of coronary artery disease, atherosclerosis, or heart failure, statins have additional benefits beyond cholesterol lowering.

**Why the Correct Answer is Right:** Statins exert pleiotropic effects, which are beneficial to the cardiovascular system. These effects include:

1. Anti-inflammatory: Statins reduce inflammation by inhibiting the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, thereby reducing the risk of atherosclerosis progression and improving overall cardiovascular health.
2. Antithrombotic: Statins inhibit platelet aggregation and reduce the risk of arterial thrombosis and embolism.
3. Vasodilatory: Statins enhance nitric oxide production, leading to vasodilation and improved coronary and peripheral blood flow.
4. Antioxidant: Statins increase the production of antioxidant enzymes that protect against oxidative stress and tissue damage.
5. Cardioprotective: Statins reduce the risk of arrhythmias, heart failure, and sudden cardiac death by improving myocardial function and preventing left ventricular remodeling.

**Why Each Wrong Option is Incorrect:**

A. Statins do lower cholesterol levels, but their primary action is not on cardiac contractility. The improvement in cardiac function occurs as a result of their pleiotropic effects mentioned above.

C. Statins do not increase the risk of myopathy or rhabdomyolysis in heart failure patients. In fact, statins are generally safe in heart failure patients, albeit with a close monitoring of electrolytes and renal function due to the potential for myopathy and rhabdomyolysis.

D. Statins do not have a negligible effect on inflammatory markers. Statins reduce inflammation, as mentioned above, which can lead to improved cardiac function and outcomes in heart failure patients.

In summary, the correct answer (B) highlights the beneficial effects of statins in heart failure patients, while the wrong options focus on the primary pharmacological action of statins (lowering cholesterol) and the potential side effects (myopathy and rhabdomyolysis). The correct answer addresses the therapeutic effects of statins in heart failure patients, which is essential for managing this condition.